In symptomatic AF with end-stage HF, adding catheter ablation to medical therapy improved clinical outcomes at 18 mo

Area of Science:

• Cardiology
• Electrophysiology
• Heart Failure Management

Background:

• End-stage heart failure (EHF) and atrial fibrillation (AF) often coexist, significantly worsening prognosis.
• Current treatments for AF in EHF patients have limited efficacy and carry substantial risks.
• Optimizing AF management in EHF is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of catheter ablation for atrial fibrillation in patients with end-stage heart failure.
• To assess the impact of catheter ablation on quality of life and clinical outcomes in this challenging population.

Main Methods:

• A prospective, multicenter study involving patients with EHF and persistent AF undergoing catheter ablation.
• Primary endpoints included quality of life assessments and reduction in heart failure hospitalizations.
• Secondary endpoints assessed arrhythmia burden, device parameters, and safety events.

Main Results:

• Catheter ablation led to a significant improvement in quality of life scores compared to baseline.
• Patients undergoing ablation experienced a significant reduction in heart failure hospitalizations.
• The procedure demonstrated an acceptable safety profile in this high-risk cohort.

Conclusions:

• Catheter ablation is a viable and effective treatment for atrial fibrillation in patients with end-stage heart failure.
• The procedure offers significant benefits in terms of quality of life and reduced hospitalizations.
• Further research should explore long-term outcomes and optimal patient selection for ablation in EHF.